Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
As of close of business last night, Enliven Therapeutics Inc’s stock clocked out at $19.01, down -4.95% from its previous closing price of $20.0. In other words, the price has decreased by -$4.95 from its previous closing price. On the day, 1.0 million shares were traded. ELVN stock price reached its highest trading level at $20.23 during the session, while it also had its lowest trading level at $18.63.
Ratios:
To gain a deeper understanding of ELVN’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 32.58 and its Current Ratio is at 32.58. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Goldman on June 16, 2025, initiated with a Buy rating and assigned the stock a target price of $37.
On December 13, 2024, BTIG Research started tracking the stock assigning a Buy rating and target price of $42.
On September 09, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $37.H.C. Wainwright initiated its Buy rating on September 09, 2024, with a $37 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Oct 20 ’25 when Lyssikatos Joseph P sold 12,500 shares for $22.08 per share. The transaction valued at 276,025 led to the insider holds 915,188 shares of the business.
Kintz Samuel sold 12,500 shares of ELVN for $266,654 on Oct 17 ’25. The PRESIDENT AND CEO now owns 902,892 shares after completing the transaction at $21.33 per share. On Oct 20 ’25, another insider, Lyssikatos Joseph P, who serves as the Officer of the company, bought 12,500 shares for $21.41 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ELVN now has a Market Capitalization of 1126067840 and an Enterprise Value of 636144768.
Stock Price History:
The Beta on a monthly basis for ELVN is 0.35, which has changed by -0.32318103 over the last 52 weeks, in comparison to a change of 0.15566266 over the same period for the S&P500. Over the past 52 weeks, ELVN has reached a high of $29.78, while it has fallen to a 52-week low of $13.30. The 50-Day Moving Average of the stock is -6.79%, while the 200-Day Moving Average is calculated to be -5.64%.
Shares Statistics:
It appears that ELVN traded 515.07K shares on average per day over the past three months and 656050 shares per day over the past ten days. A total of 59.23M shares are outstanding, with a floating share count of 41.91M. Insiders hold about 29.26% of the company’s shares, while institutions hold 76.08% stake in the company. Shares short for ELVN as of 1760486400 were 6422840 with a Short Ratio of 12.47, compared to 1757894400 on 4856687. Therefore, it implies a Short% of Shares Outstanding of 6422840 and a Short% of Float of 15.439998999999998.
Earnings Estimates
Enliven Therapeutics Inc (ELVN) is presently subject to a detailed evaluation by 1.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.5, with high estimates of -$0.5 and low estimates of -$0.5.
Analysts are recommending an EPS of between -$1.59 and -$1.59 for the fiscal current year, implying an average EPS of -$1.59. EPS for the following year is -$1.64, with 1.0 analysts recommending between -$1.64 and -$1.64.
